CAMPBELL, Calif., May 1, 2024
/PRNewswire/ -- Myra Vision, a Shifamed portfolio company,
announced today its Calibreye™ Titratable Glaucoma
Therapy™ (TGT) Surgical System, a next-generation aqueous shunt
technology, was prominently highlighted during the recent American
Society of Cataract and Refractive Surgery (ASCRS) in Boston, as well as the International Congress
on Glaucoma Surgery (ICGS) in Abu
Dhabi.
"I am optimistic that the Calibreye
Surgical System has the potential to provide a new paradigm in
glaucoma care."
Dr. Ticiana De Francesco,
Hospital de Olhos Leiria de Andrade (HOLA) in Fortaleza, Brazil and adjunct professor at
John Moran Eye Center at the University of
Utah, presented data from the company's ongoing feasibility
study (NCT 05885022) at ASCRS demonstrating laser titration of the
Calibreye Surgical System's nitinol valves and intraocular pressure
(IOP) reduction in twelve eyes. Dr. De Francesco was awarded best
paper of the session, underscoring the tremendous potential of Myra
Vision's Calibreye shunt for glaucoma care.
"I was honored to present this clinically meaningful data for
the first time at ASCRS and was thrilled to have it recognized
among the other worthy papers in our session," stated Dr. De
Francesco. "It was later brought to my attention that winning best
paper in the Company's inaugural presentation at ASCRS rarely
happens and is a credit to the innovation the technology is
bringing to glaucoma care. The Calibreye shunt is designed to
deliver an adjustable solution to control IOP in patients requiring
low IOP. This outflow control would allow glaucoma specialists to
provide personalized therapy, which is potentially revolutionary
and extremely exciting."
Once implanted, the Calibreye shunt allows physicians to
non-invasively adjust the outflow in an office visit as patient's
individual treatments needs change over time. The company is
currently enrolling patients in its feasibility study, a
prospective, non-randomized open-label study to evaluate the
clinical procedure, safety, and overall performance of the
Calibreye Surgical System in open angle glaucoma
patients.
"Glaucoma patients often experience progressive vision loss as
the condition advances," stated Dr. Keith
Barton, Moorfields Eye Hospital, Professor of Ophthalmology
at the UCL Institute of Ophthalmology and Co-Founder/Co-Chair of
the Ophthalmology Futures Forums and International Glaucoma Surgery
Registry, who subsequently presented the first-in-human proof of
principle data at the ICGS meeting. "The Calibreye Shunt features
biocompatible materials designed to conform to the native tissue
and is implanted via well-established, familiar techniques. I look
forward to additional insights from the ongoing investigation and I
am optimistic that the Calibreye Surgical System has the potential
to provide a new paradigm in glaucoma care."
In addition, Myra's innovative technology was highlighted as a
future direction in glaucoma during the Stephen A. Obstbaum MD
Honored Lecture at ASCRS by Dr. Leon
Herndon (Duke Eye Center) and at ICGS by Dr. Leon Au (Manchester Royal Eye Hospital,
Manchester, UK). The Calibreye
Surgical System will also be showcased during podium and poster
presentations at the upcoming Association for Research in Vision
and Ophthalmology (ARVO) 2024 meeting next week in Seattle, WA, again in early June during the
European Glaucoma Society (EGS) meeting in Dublin, Ireland, as well as in The Pipeline
column in an upcoming issue of Glaucoma Today.
Glaucoma, a leading cause of
irreversible blindness, affects an estimated 80M people worldwide.1 More than one
third of patients require significant reductions in IOP.
Traditionally, these glaucoma patients have been treated with
surgery, including trabeculectomy and tube shunts. Recent advances
in less invasive surgical devices offer simpler and safer treatment
options. While these devices have demonstrated an improvement in
complication rates, achieving the IOP reductions necessary for
these glaucoma patients remains challenging.
The Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical
System is for investigational use only and is not for sale in the
U.S. or outside the U.S.
About Myra Vision, Inc.
Myra Vision, Inc., a
privately held portfolio company of Shifamed LLC, is a
dynamic organization committed to advancing the future of glaucoma
care. Myra's Calibreye™ Titratable
Glaucoma Therapy™ (TGT) Surgical System is an
adjustable solution for patients with moderate to severe glaucoma
that is designed to allow safe outflow control to achieve maximum
reduction of intraocular pressure (IOP)
while also reducing complexity and complication rates. To learn
more about Myra Vision, please visit
www.myravision.com.
MEDIA CONTACT:
Katie Arnold
SPRIG Consulting LLC
katie@sprigconsulting.com
1Sheybani A, et al. Ophthalmol Ther.
2020;9(1):1-14.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/myra-visions-calibreye-titratable-glaucoma-therapy-surgical-system-showcased-at-ophthalmology-conferences-receiving-best-paper-award-and-recognition-of-future-promise-in-glaucoma-care-302133235.html
SOURCE Myra Vision, Inc.